Boehringer Ingelheim and Zealand Pharma have kicked ... consultant in metabolic medicine at University College in Dublin in Ireland, who was the principal investigator of the phase 2 trial.

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.

1,5 Full efficacy and safety data from the trial will be presented in the first half of 2025. Boehringer Ingelheim will submit a new drug application for nerandomilast for the treatment of IPF to the ...

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

Nineteen people have been arrested as gardaí dealt with a number of public order incidents at anti- and pro-immigration protests in Dublin city centre today. Several hundred people gathered on O ...